Ionis Pharmaceuticals vs Moderna: why the prices moved differently

• ▲

  Sefaxersen hits Phase 3 goal in IgA nephropathy Partner Roche reported that sefaxersen met its main Phase 3 goal in IgA nephropathy, a kidney disease, with strong protein reductions and no new safety issues. Ionis gets milestone payments and royalties, and the win shows its RNA technology works in a large market.

  This is a new clinical win that directly lifts confidence in Ionis's platform and future royalty revenue.

• ▲

  Ulefnersen succeeds in rare FUS-ALS Ionis and Otsuka said ulefnersen met its main late-stage goal in FUS-ALS, a rare inherited form of ALS, improving function and survival. No approved treatment targets this genetic cause, and they will seek accelerated approval. Ionis earns milestones and royalties.

  A second new Phase 3 success in a different disease area broadens the pipeline and adds another potential revenue stream.

Based on 6 stories →

• ▲

  FDA approves Zanvastro, first Alexander disease treatment The FDA approved Ionis' Zanvastro (zilganersen) as the first-ever treatment for Alexander disease, a rare neurological condition. This is a new commercial product and validates Ionis' RNA-targeting platform, giving the company a new revenue stream and lifting investor confidence.

  This is a major new approval that directly boosts Ionis' revenue prospects and pipeline credibility.

• ▼

  Partner Novartis' pelacarsen fails Phase 3 heart trial Novartis' pelacarsen, discovered by Ionis and licensed to Novartis, failed its Phase 3 Lp(a)HORIZON trial. It lowered Lp(a) but did not reduce cardiovascular events. Ionis shares fell 6.18% after hours. This is a setback for a partnered asset and raises doubts about the Lp(a) approach.

  This is the main negative event of the period, directly hitting Ionis' pipeline and stock price.

• ▼

  Analysts see limited financial impact from pelacarsen failure BofA and Citi analysts said the pelacarsen failure has low-single-digit downside for Ionis and should not affect 2026 guidance. Citi maintains a Buy rating and $100 target. This suggests the market may be overreacting, but the failure still removes a potential blockbuster.

  It provides context on the financial materiality of the pelacarsen failure, helping investors gauge the real impact.

• ▼

  Wainua Phase 3 failure in ATTR-CM adds to RNA silencer doubts Full Phase 3 data for Wainua (with AstraZeneca) failed to meet its primary goal in ATTR-CM. An analyst said oral stabilizers may be superior to subcutaneous silencers. This hurts Alnylam and has negative read-through for Ionis' RNA silencer technology.

  It is a separate negative trial result that questions the broader RNA silencer approach Ionis uses.

Based on 6 stories →

• ▲

  Q2 earnings beat and guidance reaffirmed Ionis reported a smaller-than-expected loss and higher revenue, and kept its 2026 sales and loss forecasts unchanged. That tells investors the core business is on track, which supports the stock even after recent trial setbacks.

  This is the period's main new positive fundamental event and directly counters the negative narrative.

• ▼

  Arrowhead's rival lipid drug succeeds, pressuring Ionis Arrowhead's plozasiran cut triglycerides by about 80% in a late-stage trial, beating Ionis's competing olezarsen. If approved, it could take market share in the same severe high-triglyceride market, making Ionis's future sales outlook less certain.

  This is a new competitive threat that directly affects Ionis's key growth market.

• ▲

  ARK ETF buys $15.3 million of Ionis shares Cathie Wood's ARK fund bought $15.3 million of Ionis stock after the trial-driven selloff. A well-known investor stepping in can steady sentiment and signal that some see the drop as overdone, though it does not change the company's fundamentals.

  This is a new capital-flow signal that helps explain the stock's stabilization after the crash.

Based on 6 stories →

• ▼

  Wainua heart trial failure and Roche's Huntington's exit Ionis and AstraZeneca's Wainua failed a Phase 3 heart trial, and Roche scrapped two partnered Huntington's programs. Shares fell about 29% in two days, wiping out a large expected revenue source and shaking confidence in the pipeline.

  This is the biggest new negative event, directly causing a sharp price drop and removing a major future revenue driver.

• ▼

  Securities fraud investigations launched Law firms Hagens Berman and Pomerantz are investigating whether Ionis misled investors about the Wainua trial's design and prospects. Legal uncertainty can pressure the stock and distract management, even if no charges are filed.

  New legal probes add a fresh layer of risk and uncertainty that can weigh on the stock price.

• ▼

  Alzheimer's drug misses primary endpoint in Phase 2 Biogen and Ionis's diranersen missed its main goal in a mid-stage Alzheimer's trial, though it showed some benefit on secondary measures. The miss is a setback for a partnered pipeline asset, but Phase 3 plans continue.

  This is a new clinical disappointment that adds to negative sentiment around Ionis's partnered programs.

• ▲

  Zilganersen licensed to Recordati and Angelman enrollment complete Ionis licensed zilganersen for Alexander disease outside the U.S. to Recordati for $30 million upfront plus royalties, and completed enrollment in the pivotal Phase 3 trial for its Angelman syndrome drug. These show pipeline progress and bring in cash.

  These are new positive developments that highlight Ionis's pipeline strength and near-term revenue potential, offering a counterweight to the negative news.

Based on 9 stories →

• ▲

  FDA approves Tryngolza for severe high triglycerides The FDA approved Tryngolza as the first treatment for severe hypertriglyceridemia, a condition affecting nearly 3 million Americans. It cuts triglycerides up to 72% and pancreatitis risk up to 91%. Ionis will launch it itself in July, opening a large new market and potential revenue stream.

  This is a major new approval that expands Ionis's commercial opportunity and drives the stock up.

• ▼

  Eplontersen fails Phase 3 ATTR-CM trial Ionis and AstraZeneca's eplontersen missed its primary endpoint in the CARDIO-TTRansform trial for ATTR-CM, a heart condition. The drug failed to reduce cardiovascular deaths or events. This removes a large expected revenue opportunity and caused Ionis shares to drop sharply.

  This is a major clinical failure that directly hurts Ionis's growth prospects and stock price.

• ▼

  Ionis stock plunges on eplontersen news Following the trial failure, Ionis shares fell as much as 19% intraday. The setback also lifted rival ATTR-CM drugs from Alnylam and BridgeBio, highlighting lost competitive ground. The full data will be presented in August, but the primary endpoint miss is a clear negative.

  This shows the immediate market reaction and competitive impact of the trial failure.

Based on 6 stories →

• ▲

  UAE investment and manufacturing talks Moderna's chairman met UAE officials to discuss investment and pharma manufacturing cooperation. This could fund expansion and open a new market, pushing the stock to a four-year high of $195.71. It shows the company is building beyond COVID.

  New event that directly lifted the stock to a multi-year high and signals growth beyond COVID.

• ▲

  Nasdaq 100 index inclusion Moderna will join the Nasdaq 100 on October 9, replacing Warner Bros. Discovery. Index funds that track the Nasdaq 100 must buy the stock, creating automatic demand. This often lifts a stock's price and adds credibility.

  New event that creates forced buying by index funds, a direct positive for the stock price.

• ▼

  Citi downgrade to sell on valuation Citi downgraded Moderna to sell, saying the stock's valuation is unjustifiable after the cancer vaccine win. The price target is 60% below the prior close. This warns that the stock may have run too far, too fast, and it fell over 6%.

  New analyst action that directly pushed the stock down and highlights valuation risk.

• ▼

  Monsanto mRNA patent lawsuit proceeds A judge rejected Moderna's bid to dismiss Monsanto's patent infringement lawsuit over its COVID vaccine. The case will continue, creating legal uncertainty and potential financial liability. This is a real counterweight to the recent good news.

  New legal development that adds uncertainty and potential cost, weighing on the stock.

Based on 8 stories →

• ▲

  FDA panel backs mRNA flu shot An FDA advisory panel voted unanimously that Moderna's mRNA flu shot, mFlusiva, is safe and effective for adults 50 and older. This clears a key regulatory hurdle and opens a second big market beyond COVID, supporting the stock.

  This is a new regulatory milestone that expands Moderna's commercial opportunity.

• ▲

  Bird flu vaccine enters Phase 3 Moderna started a late-stage trial of its mRNA bird flu vaccine with backing from an international pandemic group. It shows the mRNA platform can target new infectious diseases, adding another potential long-term growth driver.

  This is a new pipeline advancement that broadens the platform's application.

• ▲

  Cancer vaccine Phase 3 success confirmed Moderna and Merck's personalized mRNA cancer vaccine met its main goal in a large melanoma trial, cutting recurrence risk. This is the first late-stage win for an mRNA cancer therapy, opening a potential multi-billion-dollar market and driving the stock sharply higher.

  This is the core new event that re-rates Moderna's growth story.

• ▲

  Stock extends rally on cancer data MRNA jumped 6% to $154, extending a 137% one-month rally, as investors continued to bet on the melanoma vaccine data. No new company news drove the move, but the market is rewarding Moderna's specific cancer asset over rivals.

  This shows the market's ongoing positive reaction to the cancer vaccine news.

Based on 6 stories →

• ▲

  FDA approves updated COVID and first mRNA flu shots Moderna won FDA approval for updated Spikevax and mNEXSPIKE COVID vaccines and mFlusiva, the first mRNA flu shot for adults 50+. This expands its sellable respiratory portfolio, though annual uptake and pricing will decide how much it really adds.

  New regulatory approvals directly expand Moderna's product lineup and revenue potential.

• ▲

  GSK's mRNA flu vaccine advance validates platform GSK said it will move its mRNA flu vaccine into Phase III after positive Phase II results. Investors saw this as proof that mRNA works for flu, not as a threat, and Moderna shares rose nearly 10% on the news.

  A rival's progress independently validates the mRNA platform Moderna is built on.

• ▲

  August surge and $2B raise show investor conviction Moderna ended August up 156%, the top S&P 500 performer, after the melanoma trial win. It also raised $2 billion in convertible notes for its cancer vaccine business, and hedge fund holdings rose 10% to $1.5 billion.

  Confirms the cancer breakthrough is translating into real capital and sustained investor backing.

Based on 6 stories →

• ▲

  First mRNA cancer vaccine clears Phase 3 Moderna and Merck's personalized mRNA cancer vaccine, intismeran, met its main goal in a 1,137-patient melanoma trial, cutting recurrence versus Keytruda alone. This is the first late-stage win for an mRNA cancer therapy, opening a potential new market beyond vaccines and sending MRNA up as much as 177%.

  This is the single biggest new event of the period and the core reason MRNA moved.

• ▲

  Analyst upgrades and huge sales forecasts William Blair upgraded Moderna to Outperform and Wolfe Research to peer perform, while forecasts for intismeran peak sales range from $1.4 billion (Leerink) to $16.8 billion (Morningstar) by 2035. These signal professional investors see the cancer win as a durable business driver, not just a one-day pop.

  Upgrades and forecasts show whether the cancer win is treated as lasting value, which drives the stock beyond the initial spike.

• ▼

  $2.6B convertible note raise dilutes and pressures stock Moderna plans to raise $2.6 billion via convertible notes due 2032 for its cancer vaccine business and debt repayment. Convertible notes can dilute existing shareholders if converted, and the stock fell about 5% premarket and 4% intraday on the news, a real counterweight to the rally.

  This is the main new negative force this period and explains why MRNA fell for three straight sessions.

• ◆

  BioNTech's trial failure cuts both ways BioNTech halted a Phase 2 mRNA cancer vaccine trial in colorectal cancer for futility, sending its shares down 10% and dragging Moderna lower on negative read-across. But the failure also highlights Moderna's melanoma success, where it targeted a 'hot' tumor with Keytruda, strengthening its competitive position.

  This is a new event that both pressures MRNA via sector sentiment and supports its relative advantage.

Based on 23 stories →

• ▲

  First mRNA cancer vaccine wins Phase 3 Moderna and Merck's personalized mRNA cancer vaccine, intismeran, met its main goal in a large melanoma trial, cutting recurrence versus Keytruda alone. This is the first late-stage win for an mRNA cancer therapy, opening a potential new market beyond vaccines and sending MRNA up as much as 177%.

  This is the core new event that explains the period's massive move and changes Moderna's long-term growth story.

• ▲

  Analysts upgrade and raise sales forecasts BofA upgraded Moderna to Neutral with a $170 target and lifted its peak sales estimate for intismeran to $54 billion, while William Blair moved to Outperform. These upgrades signal that professional investors see the cancer win as a real, durable business driver, not just a one-day pop.

  Analyst upgrades and raised forecasts show the market is repricing Moderna's future revenue, which supports the stock beyond the initial spike.

• ▼

  Sharp pullback after record surge After the record 177% jump, MRNA fell about 20-23% the next day as some investors took profits. Such a violent swing shows the stock is now very volatile and that not everyone believes the rally is justified, which can scare off cautious investors.

  The pullback is a real counterweight to the positive news and shows the risk that the stock has run far ahead of fundamentals.

• ◆

  Valuation gap and short-seller pain Even after the surge, the average analyst price target is only about $44, far below the last close near $133, suggesting the stock may be overvalued. Short sellers lost about $5.5 billion, which can fuel further sharp moves in either direction as positions unwind.

  This highlights the tension between the exciting science and the stock's stretched valuation, a key risk for new investors.

Based on 20 stories →

• ▲

  FDA approves first mRNA flu vaccine Moderna won FDA approval for mFLUSIVA, the first mRNA-based flu vaccine, for adults 50 and older. This is a major milestone: a new product to sell and proof its mRNA technology works beyond COVID, which can lift the stock.

  This is the biggest new event, directly adding a new product and validating the platform.

• ▼

  Norovirus vaccine fails interim analysis Moderna's norovirus vaccine candidate did not meet early success criteria in a Phase 3 interim analysis, and the company will enroll more patients. This is a pipeline setback that can weigh on the stock by raising doubts about other vaccine programs.

  This is a new negative event that offsets the flu approval and affects pipeline sentiment.

• ▲

  Ebola vaccine trial starts Moderna began a Phase 1 trial of an Ebola vaccine for a strain with no approved shot, backed by up to $50 million from CEPI. It shows the mRNA platform can target new diseases, supporting the long-term growth story even if revenue is years away.

  This is a new pipeline milestone that broadens the platform's potential beyond COVID and flu.

• ▼

  Arbutus settlement payment Arbutus received a $178 million payment from Moderna as part of a $950 million patent settlement. This is cash leaving Moderna and a reminder that legal costs from past patent disputes continue to weigh on finances.

  This is a new cash outflow event that affects Moderna's financial position.

Based on 6 stories →

• ▲

  Q2 earnings beat and outlook reaffirmed Moderna beat second-quarter revenue and loss estimates and reaffirmed its full-year growth target. This shows the business is performing better than expected, which supports the stock price by reducing fears about cash burn and future funding needs.

  This is the main new financial event of the period and directly affects investor confidence in MRNA.

• ▲

  FDA decision on mRNA-1010 flu vaccine due August 5 An FDA ruling on Moderna's standalone flu shot is expected within days. Approval would give Moderna a fifth commercial product and help rebuild its respiratory vaccine business, potentially lifting the stock if the decision is positive.

  This is a near-term regulatory catalyst that could significantly change MRNA's product lineup and revenue outlook.

• ▼

  Norovirus vaccine trial misses early metric Moderna's norovirus vaccine trial missed an early goal, disclosed alongside earnings. This is a setback for a pipeline candidate and may dampen enthusiasm about the company's broader vaccine prospects, weighing on the stock.

  This is a new negative development that tempers the positive earnings news and highlights pipeline risk.

• ▲

  Strong Q1 revenue growth and AI ranking Moderna's Q1 revenue surged 260% year-over-year, the fastest among therapeutics stocks, and it ranked third in an investor survey of AI integration. These reinforce the growth narrative and positive sentiment, though the AI angle is not a major valuation driver.

  This provides context on Moderna's recent financial momentum and investor perception, supporting the bull case.

Based on 7 stories →

• ▲

  Analyst upgrade and Cramer's bullish turn Piper Sandler raised its price target, and Jim Cramer said Moderna is investable again, citing the pipeline shift into cancer, rare diseases, and a new flu shot. These endorsements drew new buyers, pushing the stock up sharply.

  New analyst and media endorsements directly lifted investor sentiment and the stock price.

• ▲

  Science Day fuels mRNA expansion hopes Moderna's Science Day showcased plans to move beyond vaccines into cancer therapies, autoimmune treatments, and an in vivo CAR-T candidate. Investors saw a broader future beyond COVID, driving the stock to a 52-week high and adding billions in market value.

  The Science Day event was a major catalyst that expanded the growth story and attracted investors.

• ▼

  Vaccine skepticism resurfaces Renewed political focus on vaccine skepticism sent Moderna shares down nearly 11% in one day. This shows that political and public-health headwinds can still hit the stock hard, even as the pipeline improves.

  This is a new negative development that highlights a real risk to Moderna's core vaccine business.

• ▼

  Patent settlement cash outflow Moderna paid $178 million to Arbutus as part of a patent settlement. While the amount is smaller than earlier settlements, it is still cash out the door and a reminder that legal costs continue to weigh on finances.

  This new payment is a concrete financial hit and shows ongoing litigation costs.

Based on 6 stories →

• ▲

  Science Day showcases pipeline beyond COVID Moderna's Science Day highlighted progress in cancer, autoimmune, and next-generation mRNA treatments, including its first cancer prevention program and a multiple sclerosis therapy. This expands the company's potential beyond COVID vaccines, giving investors new reasons to believe in future growth and pushing the stock up.

  This is the main new event of the period and directly explains the stock's surge.

• ▲

  FDA panel backs flu vaccine, approval decision in August An FDA advisory panel voted 9-0 in favor of Moderna's mRNA flu vaccine for adults 50 and older, making final approval by August 5 much more likely. A new revenue stream would reduce reliance on COVID vaccines, boosting investor optimism and the stock price.

  This is a new regulatory milestone that de-risks a key product and supports the stock's rise.

• ▲

  Strong Q1 revenue growth beats expectations Moderna's first-quarter revenue jumped 260% year over year to $389 million, beating analyst estimates by 55.8%. This shows the business is growing faster than expected, which supports the stock price even though the company still posted a loss.

  This new earnings data provides fundamental support for the stock's recent gains.

• ◆

  Analysts still cautious despite strong run Even after the stock surged nearly 42% in a month, Quant Ratings, Seeking Alpha analysts, and Wall Street analysts maintain a Hold rating. This suggests that while the pipeline is promising, significant risks remain, which could limit further upside or lead to pullbacks.

  This provides a fair counterweight to the positive news and explains why the stock isn't rated a buy.

Based on 7 stories →

• ▲

  FDA panel unanimously backs Moderna's flu vaccine An FDA advisory committee voted 9-0 that Moderna's mRNA flu vaccine is safe and effective for adults 50 and older. This key endorsement makes approval by the August 5 deadline much more likely, opening a new revenue stream and boosting investor confidence.

  This is the main new event that directly lifts MRNA's price by de-risking a major product approval.

• ▲

  Moderna plans three new vaccine launches by 2028 Moderna said it will launch a combined flu-COVID shot, a seasonal flu vaccine, and a norovirus vaccine between 2027 and 2028. It also expects important trial results this year for a personalized cancer therapy and a rare disease treatment, which could lead to its first oncology and rare disease products.

  This new pipeline update shows future growth beyond COVID vaccines, supporting a higher stock price.

• ▼

  Moderna to pay $2.25 billion in patent settlement Moderna agreed to a $2.25 billion global settlement with Roivant Sciences to resolve patent-infringement litigation. This is a large cash outflow that reduces Moderna's financial flexibility and is a real cost, even though it removes a legal cloud.

  This new settlement is a significant negative financial event that weighs on MRNA's price.

Based on 7 stories →